Feature | Contrast Media Injectors | January 30, 2020 | By Matthew Kuhn, M.D., FACR

Artificial Intelligence Processes Provide Solutions to Gadolinium Retention Concerns

There is more in a medical image than the human eye can understand, and AI can help radiologists make better decisions

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma

This image is of an 80 kg woman with a newly diagnosed IDH-wildtype glioblastoma. The quarter dose image on the left was obtained after the administration of 4 ml of MultiHance. Subsequently, an additional 12 ml of MultiHance was administered and the cumulative full dose image in the center was obtained. The image on the right was rendered following artificial intelligence processing of the 4 ml image using eGad genetic algorithms. This image has the quality of triple dose gadolinium even though only one quarter dose gadolinium was given.

Matthew Kuhn, M.D., FACR

Matthew Kuhn, M.D., FACR

Gadolinium-based contrast agents (GBCAs) are widely used in medical imaging to provide essential diagnostic information from magnetic resonance imaging (MRI) scans. These injections help a radiologist examine images more accurately by improving the visibility and the clarity of many abnormalities and for achieving maximum diagnostic quality.

However, recent research has shown that gadolinium agents may remain in the body — including the liver, bone and brain — for months or even years after injection.1 This has stoked fears of adverse clinical outcomes from the use of GBCAs. It remains unclear if there are any neurological signs or symptoms associated with gadolinium retention although it must be considered that up to now, no negative health effects can be attributed to gadolinium retention in the brain.2,3

Despite agreement among the American College of Radiology (ACR) and the U.S. Food and Drug Administration (FDA) that gadolinium retention is not known to have adverse outcomes in patients,2,3 some practitioners still have concerns about the use of GBCAs. Would those concerns be alleviated if lower levels of the safest GBCAs could be used?

Using Algorithms to Test GBCAs

To address this question, A. I. Analysis, Inc., a Seattle-based medical software company, designed genetic algorithms that allow for the use of lower dose GBCAs. When low dose gadolinium was injected into patients and the resultant images were processed using these artificial intelligence (AI) techniques (eGad), the resultant images all equaled or exceeded the quality of full contrast dose images. Additionally, A. I. Analysis, Inc. used its advanced, layered machine learning system tools to verify that equimolar doses of the standard concentration gadoteridol (ProHance), a macrocyclic contrast agent which has been shown from animal studies to result in less retention one month after injection compared to other agents,4,5 is non-inferior to the more concentrated gadolinium agent gadobutrol (Gadavist).6

In the GBCA comparison study, 32 patients with glioblastoma (GBM) received both ProHance and Gadavist using double-blind, randomized crossover methodology. To evaluate the images, the authors used the Quantitative Enhancement Analysis software of A.I. Analysis, Inc. The software identified no statistically significant difference in enhancement characteristics between the standard concentration of ProHance and the double concentration of Gadavist when administered at the same equimolar dose of 0.1 mmol/kg. This confirmed the findings of the original TRUTH study,7 a landmark gadolinium contrast agent comparison study from 2015, which found no benefit to the use of higher concentrations of gadolinium using traditional comparison techniques.

Additionally, 50 patients with known contrast enhancing brain tumors initially received either 1/10, 1/4, 1/3 or 1/2 dose of a high relaxivity GBCA (gadobenate dimeglumine, MultiHance) and routine images were acquired. Subsequently, the remaining cumulative full dose images were acquired. The original low dose images were processed using the eGad synthetic enhancement tool of A.I. Analysis, Inc., and three blinded readers confirmed that the low dose eGad images achieved image quality equal or greater than the cumulative full dose images. 

Using AI Applications

In light of concerns about gadolinium retention, these findings will help radiologists make the best decisions with and for their patients with confidence. The use of AI tools for future studies will allow for more sophisticated research and improved results.

As we enter 2020, the use of AI applications to compare agents and medical images will become more common. As these studies demonstrate, the use of AI in research can rapidly produce findings that are both transparent and replicable, the hallmarks of scientific validity. 

There is more in a medical image than the human eye can understand, and AI can help us make better decisions and better treatment plans for our patients.

Key results described here were presented at the 2019 Radiological Society of North America (RSNA) meeting. 

Matthew Kuhn, M.D., FACR, is board certified in neuroradiology and diagnostic radiology and holds certificates of proficiency in coronary CT angiography and cardiac and peripheral vascular MRI from the American College of Radiology. Kuhn is a clinical professor at the University of Illinois College of Medicine in Peoria, Ill. and is a practicing radiologist with Radiology Partners.   

Disclosure: Matthew Kuhn, M.D., FACR serves as chief medical officer for A.I. Analysis, Inc., a company that has its roots in fully automated and reproducible change detection, and its eyes on a future in which AI broadly enhances radiologist performance and patient well-being, by turning information overload into information affluence.

References:

1. McDonald RJ, et al. Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 289(2): 517-534 2018

2. ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media. Version 10.3.2018. Accessed January 2019.

3. FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. FDA website. https://www.fda.gov/Drugs/DrugSafety/ucm223966.htm. Accessed December 19, 2018.

4. Bussi S, et al. Differences in Gadolinium Retention After Repeated Injections of Macrocyclic MR Contrast Agents to Rats. J Magn Reson Imaging. 2018; 47:746-752

5. McDonald RJ, et al. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear Versus Macrocyclic Gadolinium Chelates. Radiology 285:2: 2017

6. Kuhn MJ, Patriarche JW. The Use of Artificial Intelligence to Evaluate Differences in Contrast Enhancement between Two Macrocyclic Gadolinium Agents in Patients with Glioblastoma Multiforme [abstract]. In: Proceedings of the 105th Annual Meeting of the Radiological Society of North America.  2019 Dec 1–6; Chicago, IL. Abstract nr SSM21-04.

7. Maravilla KR et al. Are there differences between macrocyclic gadolinium contrast agents for brain tumor imaging? Results of a multicenter intraindividual crossover comparison of gadobutrol with gadoteridol (the TRUTH study). AJNR Am J Neuroradiol. 2015;36(1):14-23.  

 

Related Content of MRI Gadolinium Safety Concerns

The Debate Over Gadolinium MRI Contrast Toxicity

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety

Recent Developments in Contrast Media

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents

European Medicines Agency Issues Update on Gadolinium Contrast Agents

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents

FDA: No Harm in MRI Gadolinium Retention in the Brain

VIDEO: MRI Gadolinium Contrast Retention in the Brain

Gadolinium May Remain in Brain After Contrast MRI

 

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Surgeon General Jerome Adams, M.D., M.Ph demonstrates how the general public can make their own face masks for non-clinical use.

U.S. Surgeon General Jerome Adams, M.D., M.Ph. demonstrates how the general public can make their own face masks for non-clinical use.

News | Coronavirus (COVID-19) | April 04, 2020 | By Melinda Taschetta-Millane
April 4, 2020 — The Centers for Disease Control and Prevention (CDC)
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Jeannie Danker, M.D. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Jeannie Danker, M.D. Photo courtesy of The Ohio State University Wexner Medical Center

News | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane
April 3, 2020 — The radiology world has lost a dedicated leader due to...
An estimated 44 million people worldwide are currently living with Alzheimer’s disease, the most common form of dementia. About 5.8 million people in the United States live with the disease, where it is the sixth leading cause of death overall. While there is not yet a cure for Alzheimer’s, researchers are working to find treatment options to delay its onset and prevent it from developing.

Image courtesy of Insightec

Feature | Ultrasound Imaging | April 02, 2020 | By Katie Caron
An estimated 44 million people worldwide are currently living with...
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus

Getty Images

Feature | Coronavirus (COVID-19) | April 02, 2020 | Jilan Liu and HIMSS Greater China Team
Information technologies have played a pivotal role in China’s response to the novel coronavirus...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

News | Ultrasound Imaging | April 02, 2020
April 2, 2020 — Esaote, an Italian company among the world leader